Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-05-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-3243PMID 20460483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• Inhibition of murine γδ lymphocyte expansion and effector function by regulatory αβ T cells is cell‐contact‐dependent and sensitive to GITR modulation

  2009cited by this paper
• Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor‐specific CD8+ T cells

  2009cited by this paper
• Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.

  2009cited by this paper
• Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

  2008cited by this paper
• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

  2008cited by this paper
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

  2008cited by this paper
• Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells

  2008cited by this paper
• Perspectives of gammadelta T cells in tumor immunology.

  2007cited by this paper
• Perspectives of γδ T Cells in Tumor Immunology: Figure 1.

  2007cited by this paper
• Effector and memory CTL differentiation.

  2007cited by this paper
• The GITR–GITRL interaction: co-stimulation or contrasuppression of regulatory activity?

  2006influential reference
• Engagement of Glucocorticoid-Induced TNF Receptor Costimulates NKT Cell Activation In Vitro and In Vivo1

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• NY-ESO-1: review of an immunogenic tumor antigen.

  2006cited by this paper
• In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

  2006cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

  2005cited by this paper
• A function for interleukin 2 in Foxp3-expressing regulatory T cells

  2005cited by this paper
• Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

  2005cited by this paper
• IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1

  2005cited by this paper
• IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.

  2005cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• Immune recognition of self in immunity against cancer.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity

  2001cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody

  1999cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

  1999cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper
• CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production

  1998cited by this paper
• The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

  1996cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

  1995cited by this paper
• A colon tumor model for anticancer agent evaluation

  1975cited by this paper

• Progress and Future Perspectives of Treg Cell Therapy.

  2025cites this paper
• Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade.

  2025cites this paper
• Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects

  2024cites this paper
• Tumor necrosis factor superfamily signaling: life and death in cancer

  2024cites this paper
• A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

  2024cites this paper
• Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review

  2024cites this paper
• Immunotherapy for colorectal cancer

  2024cites this paper
• CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy

  2023cites this paper
• Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

  2022cites this paper
• Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells

  2022cites this paper
• Development of a fully human anti‐GITR antibody with potent antitumor activity using H2L2 mice

  2022cites this paper
• Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

  2022cites this paper
• Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

  2022cites this paper
• Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential

  2021cites this paper
• External stimuli-responsive nanomedicine for cancer immunotherapy

  2021cites this paper
• Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts

  2021cites this paper
• Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

  2021cites this paper
• Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T cell activation.

  2021cites this paper
• Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

  2020cites this paper
• New emerging targets in cancer immunotherapy: the role of GITR

  2020cites this paper
• Characterization and Comparison of GITR Expression in Solid Tumors

  2019cites this paper
• Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids

  2019cites this paper
• Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.

  2019cites this paper
• Application Of Adoptive Immunotherapy In Ovarian Cancer

  2019cites this paper
• OTT_A_221773 7975..7991

  2019cites this paper
• Combining immunotherapies to treat non-small cell lung cancer

  2019cites this paper
• Integrated cancer tissue engineering models for precision medicine

  2019cites this paper
• Rational design of anti-GITR-based combination immunotherapy

  2019cites this paper
• Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer

  2018cites this paper
• Emerging strategies for combination checkpoint modulators in cancer immunotherapy

  2018cites this paper
• Harnessing immune checkpoints for cancer therapy.

  2018cites this paper
• Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression

  2018cites this paper
• Functional Characterization of Potential New Agents for Cancer Immunotherapy

  2018cites this paper
• New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

  2018cites this paper
• Combination immune checkpoint blockade as an effective therapy for mesothelioma

  2018cites this paper
• Therapeutic cancer vaccine: building the future from lessons of the past

  2018cites this paper
• The tumor microenvironment: Thousand obstacles for effector T cells.

  2017cites this paper
• Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities

  2017cites this paper
• Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells

  2017cites this paper
• Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

  2017cites this paper
• Immune checkpoint blockade in infectious diseases

  2017cites this paper
• A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

  2017cites this paper
• Oncolytic virotherapy : the story so far

  2017cites this paper
• Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice

  2017cites this paper
• Prospects for combined use of oncolytic viruses and CAR T-cells

  2017cites this paper
• Myeloid‐derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force

  2017cites this paper
• Immunotherapy-based combinations: current status and perspectives

  2017cites this paper
• Chemical Carcinogenesis Models of Cancer: Back to the Future

  2017cites this paper
• The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches

  2016cites this paper
• Role of regulatory T cells and associated chemokines in human gynecological tumors

  2016cites this paper
• Rationale for anti-GITR cancer immunotherapy.

  2016cites this paper
• Combinatorial Cancer Immunotherapies.

  2016cites this paper
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

  2016cites this paper
• Roles of regulatory T cells in cancer immunity.

  2016cites this paper
• Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.

  2016cites this paper
• Strategies to Improve the Efficacy of Vaccines by Selective Manipulation of the Immune System: A Translational Study

  2016cites this paper
• Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination

  2016cites this paper
• The role of glycosylation in regulatory T-cell biology

  2016cites this paper
• Combinatorial approach to cancer immunotherapy: strength in numbers

  2016cites this paper
• Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

  2016cites this paper
• Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

  2016cites this paper
• Mechanisms of immunological tolerance.

  2016cites this paper
• Targeting regulatory T cells in tumors

  2016cites this paper
• Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.

  2015cites this paper
• Checkpoint blockade in combination with cancer vaccines.

  2015cites this paper
• Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1

  2015cites this paper
• Integrative network modeling approaches to personalized cancer medicine.

  2015cites this paper
• Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

  2015cites this paper
• PAMPering immune responses : spotlight on helper cells for dendritic cell vaccination

  2015cites this paper
• The T Cell Co-stimulatory Molecule GITR in the Control and Treatment of a Persistent Viral Infection

  2015cites this paper
• T-Cell Costimulation and Its Applications in Diseases

  2015cites this paper
• Foxp3 + Treg cells in gastric cancer: recent progress

  2015cites this paper
• Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

  2015cites this paper
• Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect

  2015cites this paper
• Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.

  2015cites this paper
• The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

  2015cites this paper
• Review Article Immunotherapy for colorectal cancer

  2015cites this paper
• Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

  2015cites this paper
• Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection.

  2014cites this paper
• Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

  2014cites this paper
• 64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues

  2014cites this paper
• The translation of cancer genomics: time for a revolution in clinical cancer care

  2014cites this paper
• Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor

  2014cites this paper
• Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti‐tumor effect of the CTLA‐4 blockade in an HLA‐DR transgenic mouse model of prostate cancer

  2014cites this paper
• Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer

  2014cites this paper
• GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma

  2014cites this paper
• Regulatory T cells in cancer immunotherapy.

  2014cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy

  2014cites this paper
• Glucocorticoid-Induced TNF Receptor (GITR)

  2013cites this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cites this paper
• VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.

  2013cites this paper
• Therapeutic Targeting Regulatory T Cells in Tumor

  2013cites this paper
• Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

  2013cites this paper
• Natural and Induced T Regulatory Cells in Cancer

  2013cites this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cites this paper
• A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.

  2013cites this paper
• Antibody-based therapy in colorectal cancer.

  2013cites this paper
• Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

  2013influential citation
• Advances in the development of cancer immunotherapies.

  2013cites this paper
• CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma

  2012cites this paper